Welcome to our dedicated page for Bluebird Bio news (Ticker: BLUE), a resource for investors and traders seeking the latest updates and insights on Bluebird Bio stock.
bluebird bio (BLUE) was a biotechnology company focused on gene therapies for severe genetic diseases until its acquisition by Carlyle and SK Capital Partners in June 2025. The acquisition resulted in the company's delisting from NASDAQ, ending its existence as a publicly traded entity. Shareholders received either $3.00 per share plus contingent value rights or $5.00 per share in cash in a transaction valued at approximately $29 million.
The sale followed significant financial challenges including cash constraints, workforce reductions of 25%, and going-concern warnings. The company had struggled to achieve commercial success with its three FDA-approved gene therapies despite being among the first to bring cell-based gene therapies to market. Competition in the sickle cell disease market, slower-than-expected patient uptake, reimbursement challenges related to multi-million dollar price tags, and safety concerns contributed to the financial pressure that led to the strategic sale.
Under new private ownership, the company rebranded as Genetix Biotherapeutics and continues commercializing its approved therapies: Zynteglo for beta-thalassemia, Lyfgenia for sickle cell disease, and Skysona for cerebral adrenoleukodystrophy. News related to bluebird bio may cover topics including gene therapy market trends, regulatory updates on approved therapies, safety monitoring results, patient access and reimbursement developments, competition in rare disease treatments, and the evolution of the commercial gene therapy industry.
bluebird bio reported strong momentum in its commercial gene therapy initiatives for ZYNTEGLO and SKYSONA, with 7 patient starts to date. The company is advancing its Biologics License Application (BLA) for lovo-cel targeting sickle cell disease, with an anticipated FDA response soon. Financially, bluebird's Q4 2022 revenue was $0.06 million, down from $1.6 million in Q4 2021, while total revenue for 2022 was $3.6 million, slightly lower than the prior year. The company has a cash position of approximately $227 million but expects a cash burn between $270-$300 million for 2023. Despite losses, significant progress in therapies and operational efficiency was noted.
bluebird bio, Inc. (Nasdaq: BLUE) has priced an underwritten public offering of 20,000,000 shares of common stock at $6.00 per share, potentially raising gross proceeds of $120 million. The offering includes an option for underwriters to purchase an additional 3,000,000 shares. Funds will support commercialization and manufacturing of approved gene therapies ZYNTEGLO and SKYSONA, accelerate activities for the gene therapy candidate lovo-cel, and cover general corporate purposes. The offering is expected to close on or about January 23, 2023, pending customary conditions.
bluebird bio has initiated a public offering of 20 million shares of its common stock, with a possible additional 3 million shares available for underwriters. The offering's specifics depend on market conditions and completion is uncertain. The funds will support commercialization and manufacturing of its gene therapies, including ZYNTEGLO and SKYSONA, accelerate activities for lovotibeglogene autotemcel (lovo-cel) if approved, and cover working capital needs. The public offering is registered with the SEC under an effective shelf registration statement.
bluebird bio announced progress updates ahead of the J.P. Morgan Healthcare Conference, highlighting significant milestones in their commercial gene therapy launches. The first commercial treatment of ZYNTEGLO has begun, with expected revenue in Q1 2023. The company also confirmed that the lovo-cel BLA submission is on track for Q1 2023. As of December 31, 2022, bluebird reported approximately
bluebird bio, Inc. (NASDAQ: BLUE) has successfully sold its second Rare Pediatric Disease Priority Review Voucher (PRV) for $95 million, enhancing its financial strength without diluting shareholder equity. This follows a similar transaction last year where the company sold its first PRV for $102 million. The funds are expected to support the commercial launches of its FDA-approved gene therapies, ZYNTEGLO and SKYSONA, while bolstering the company's position in the sickle cell disease market.
bluebird bio (Nasdaq: BLUE) will present a corporate update at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 7:30 AM PT. CEO Andrew Obenshain will lead the session. Investors can access the live webcast on the bluebird bio website, where a replay will be available for 30 days. bluebird bio focuses on curative gene therapies for severe genetic diseases, including sickle cell disease and β-thalassemia, and is known for its industry-leading data in ex-vivo gene therapy.
bluebird bio, Inc. (Nasdaq: BLUE) has appointed
bluebird bio announced that the FDA has lifted its partial clinical hold on lovotibeglogene autotemcel (lovo-cel) for patients under 18 with sickle cell disease (SCD). The company plans to resume enrollment and treatment of pediatric patients in Q1 2023, following a thorough investigation into previous anemia cases related to the treatment. bluebird is on track to submit a Biologics License Application for lovo-cel by the end of Q1 2023, having met FDA requirements and updated exclusion criteria for ongoing trials.
bluebird bio presented updated data on its gene therapies for beta-thalassemia and sickle cell disease at the ASH Annual Meeting. Key findings for ZYNTEGLO (beti-cel) include 90.2% of beta-thalassemia patients achieving transfusion independence, with long-term follow-up showing durable treatment effects. Lovo-cel's data revealed two anemia cases linked to alpha-thalassemia trait. A BLA for lovo-cel is anticipated by Q1 2023. Safety profiles for both therapies were consistent with known side effects, and ongoing studies continue to advance understanding of treatment safety and efficacy.
bluebird bio announced a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $102 million. The PRV was awarded due to FDA approvals of its gene therapies, ZYNTEGLO and SKYSONA, in 2022. CEO Andrew Obenshain stated that this non-dilutive capital strengthens the company's financial outlook, aiding the launches of these therapies and upcoming milestones, including a BLA submission for lovo-cel for sickle cell disease. The transaction, subject to closing conditions, marks a significant financial maneuver for the company.
FAQ
What is the current stock price of Bluebird Bio (BLUE)?
What is the market cap of Bluebird Bio (BLUE)?
